Alembic Pharmaceuticals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Alembic Pharmaceuticals Q2 results FY27 announcement is the next scheduled earnings event for Alembic Pharmaceuticals Ltd., a maker of pharmaceutical formulations and active ingredients, selling generics across India, the United States and other international markets. The stock traded at Rs 804.75 on the NSE on 9 September 2026, down 0.46% from the previous close of Rs 808.50, about 19.4% below its 52-week high of Rs 998.00 and 26.6% above its 52-week low of Rs 635.80.

What makes the Alembic Pharmaceuticals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 1,910.00 crore of revenue and a profit of Rs 184.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 2,150.00 crore and a profit of Rs 172.00 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Alembic Pharmaceuticals Q2 Results FY27 Date?

The Alembic Pharmaceuticals Q2 results date for FY27 is not confirmed. As of 9 September 2026, Alembic Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Alembic Pharmaceuticals Q2 results date becomes public through that filing rather than through any advance announcement.

The Alembic Pharmaceuticals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Alembic Pharmaceuticals.

Alembic Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Alembic Pharmaceuticals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Alembic Pharmaceuticals. The Alembic Pharmaceuticals Q2 results watchlist below is built from what the company has actually reported and disclosed.

The first is the United States generics business, where price erosion and new product approvals pull in opposite directions. Revenue reached a five-quarter high of Rs 2,150 crore in June 2026 against Rs 1,910 crore in September 2025.

The second is margin. September 2025 recorded the best operating margin of the five at 17%, against 15% in the most recent quarter, so this year's comparison is against a demanding base on that measure.

The third is that the March 2026 profit of Rs 202 crore came with a tax credit on the weakest operating quarter of the five. Reading September against March on reported profit alone would give a misleading picture.

Check Alembic Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener

Alembic Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Alembic Pharmaceuticals Ltd. reported revenue of Rs 2,150.00 crore in Q1 FY27, up 25.66% from Rs 1,711.00 crore in Q1 FY26, and a profit of Rs 172.00 crore at the net level, up 11.69% from Rs 154.00 crore in Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was up 16.34% over the March 2026 quarter figure of Rs 1,848.00 crore, and net profit was down 14.85% from Rs 202.00 crore in Q4 FY26. Operating margin stood at 15% in Q1 FY27 against 17% in the September 2025 quarter, which is the comparison the Alembic Pharmaceuticals Q2 results print will be read against.

Q2 FY26 Base: The Comparison Alembic Pharmaceuticals Q2 Results FY27 Must Beat

Alembic Pharmaceuticals Ltd. reported revenue of Rs 1,910.00 crore and a profit of Rs 184.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Alembic Pharmaceuticals Q2 results preview.

Net profit in that base quarter was above the Rs 172.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 1,910.00 crore sits below the Rs 2,150.00 crore of the June 2026 quarter, which frames how much sequential movement the Alembic Pharmaceuticals Q2 results print needs to show growth.

Alembic Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	1,910.00	184.00
Q3 FY26 (Dec 2025)	1,876.00	132.00
Q4 FY26 (Mar 2026)	1,848.00	202.00
Q1 FY27 (Jun 2026)	2,150.00	172.00

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Alembic Pharmaceuticals Q2 results preview uses.

Revenue across those four quarters ranged from Rs 1,848.00 crore to Rs 2,150.00 crore, and net profit from Rs 132.00 crore to Rs 202.00 crore. That spread is the honest context for the Alembic Pharmaceuticals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Alembic Pharmaceuticals Q2 Results FY27

The Alembic Pharmaceuticals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Alembic Pharmaceuticals has already reported.

United States Approvals and Price Erosion

Generic approvals add revenue while competition erodes the price of existing products. The net of those two, disclosed in the results commentary, explains the export revenue line better than the headline growth figure.

India Branded Business and Specialty

The domestic branded portfolio and the specialty segment carry different margins from commodity generics, so the geographic and product mix decides where in the 12% to 17% band the operating margin lands.

Watch the Line Below Operating Profit

December 2025 carried negative other income of Rs 27 crore and March 2026 a tax write-back, while operating profit told a different story in both. This is a company where the reported profit and the operating result need reading separately.

Alembic Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print

Alembic Pharmaceuticals share price today is Rs 804.75 on the NSE, down Rs 3.75 or 0.46% from the previous close of Rs 808.50 on 9 September 2026, ahead of the Alembic Pharmaceuticals Q2 results announcement.

Metric	Value (9 September 2026)
NSE Symbol	APLLTD
Current Market Price	Rs 804.75
52-Week High	Rs 998.00
52-Week Low	Rs 635.80
Market Capitalisation	Rs 15,814 crore
PE Ratio	21.14
PB Ratio	2.78
EPS (TTM)	Rs 38.07
Book Value per Share	Rs 289.00
Debt to Equity	0.25
Return on Equity	13.40%
50-Day Moving Average	Rs 821.09
200-Day Moving Average	Rs 787.57
RSI (14)	47.00

The stock trades below its 50-day average of Rs 821.09 but above its 200-day average of Rs 787.57, with a 14-day RSI of 47.00. None of this is a view on where the shares go once the Alembic Pharmaceuticals Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Alembic Pharmaceuticals Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Alembic Pharmaceuticals Q2 results print in proportion.

1. Revenue against the Rs 1,910.00 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 184.00 crore in that same quarter
3. Operating margin against 15% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Alembic Pharmaceuticals Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Alembic Pharmaceuticals Q2 Results FY27

The Alembic Pharmaceuticals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Alembic Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Alembic Pharmaceuticals Q2 results FY27 print faces a base of Rs 1,910.00 crore in revenue and a profit of Rs 184.00 crore, with the most recent quarter having delivered Rs 2,150.00 crore and a profit of Rs 172.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Alembic Pharmaceuticals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Alembic Pharmaceuticals Q2 Results FY27

What is the Alembic Pharmaceuticals Q2 results date for FY27?

Ans. The Alembic Pharmaceuticals Q2 results date for FY27 is not confirmed. Alembic Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Alembic Pharmaceuticals Q2 results 2026 cover?

Ans. The Alembic Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Alembic Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Alembic Pharmaceuticals Q2 results filing also carries the notes to the accounts.

What were the Alembic Pharmaceuticals Q1 FY27 results?

Ans. Alembic Pharmaceuticals Ltd. reported revenue of Rs 2,150.00 crore in Q1 FY27 and a profit of Rs 172.00 crore at the net level. Revenue was up 25.66% versus Q1 FY26 and net profit was up 11.69% from Rs 154.00 crore in Q1 FY26.

What were Alembic Pharmaceuticals Q2 FY26 results in the September 2025 quarter?

Ans. Alembic Pharmaceuticals Ltd. reported revenue of Rs 1,910.00 crore and a profit of Rs 184.00 crore in Q2 FY26. Operating margin was 17%. Those figures form the base for the Alembic Pharmaceuticals Q2 results FY27 comparison.

What are the main Alembic Pharmaceuticals Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Alembic Pharmaceuticals Q2 results expectations centre on revenue against the Rs 1,910.00 crore base, net profit against a profit of Rs 184.00 crore, operating margin against 15% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Alembic Pharmaceuticals share price today ahead of the Q2 earnings?

Ans. Alembic Pharmaceuticals share price is Rs 804.75 on the NSE as of 9 September 2026, down 0.46% from Rs 808.50. The stock is about 19.4% below its 52-week high of Rs 998.00 and 26.6% above its 52-week low of Rs 635.80, at a market capitalisation of Rs 15,814 crore.

Is Alembic Pharmaceuticals a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Alembic Pharmaceuticals Ltd.. The stock trades at a price-to-book ratio of 2.78 with a return on equity of 13.40%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.